Ontology highlight
ABSTRACT: Background
N-acetyl cysteine (NAC) appears promising as a treatment in patients with substance use disorder (SUD) as it helps rebalance glutamate levels in the central nervous system (CNS). Basal concentrations of glutamate are indeed reduced in SUD patients but increased during craving.Materials and methods
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs). We assessed whether NAC reduce craving rating as compared to a placebo in SUD patients. Secondary outcomes were withdrawal symptoms (WS), side effects (SE) and drop-outs. Estimates are presented as standardized mean differences (SMD) or risk ratio (RR) with 95% confidence interval (CI).Results
Eleven RCTs were included. NAC reduced craving rating (SMD -0.61 (-1.17, -0.06),
SUBMITTER: Cuocina M
PROVIDER: S-EPMC11412889 | biostudies-literature | 2024
REPOSITORIES: biostudies-literature